Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 1/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.34 |
| ▸ | SYK | P43405 | 2/20 | 0.32 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.32 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25822678 | 0.72 | MAPKAPK5 (0.52) | SYK | |
| SCHEMBL24832406 | 0.70 | MAPK8 (0.44) | IKBKBMAPK8SYK | |
| SCHEMBL169235 | 0.70 | MAPK8 (0.54) | MAPK8ADORA2AADORA1 | |
| SCHEMBL31746758 | 0.70 | MAPK8 (0.54) | MAPK8ADORA2AADORA1 | |
| SCHEMBL24541113 | 0.69 | MAPK8 (0.57) | IKBKBMAPK8 | |
| SCHEMBL24541135 | 0.68 | MAPK8 (0.47) | IKBKBMAPK8 | |
| SCHEMBL29138850 | 0.65 | IKBKB (0.36) | IKBKBMAPK8ADORA2AGRIA1 | |
| SCHEMBL31329391 | 0.65 | NPC1 (0.62) | ADORA1 | |
| SCHEMBL23037694 | 0.64 | DHFR (0.36) | SYK | |
| SCHEMBL2531557 | 0.63 | DYRK1A (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219960-A1 | 1H-PYRAZOLE DERIVATIVE AND APPLICATION THEREOF AS DUAL TARGET INHIBITOR OF SYK AND VEGFR2 | OCUMENSION THERAPEUTICS (SUZHOU) CO., LTD. (CN) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219960-A1 | 1H-PYRAZOLE DERIVATIVE AND APPLICATION THEREOF AS DUAL TARGET INHIBITOR OF SYK AND VEGFR2 | SYK, KDR, FLT1 | IKBKB 275/4885MAPK8 637/4885SYK 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.